Skip to content
Fat BurnerWADA ProhibitedCompare

Ephedrine

Also known as: Ephedra, ECA Stack, Ma Huang

5
1 · Natty510 · Enhanced

Lower numbers = closer to natural. Higher numbers = more enhanced.

Why this rating?

Per the Shekelle et al. (2003) JAMA meta-analysis, ephedrine (with or without caffeine) produces ~0.9 kg/month weight loss above placebo (pooled estimates ranging 0.6-1.3 kg/month depending on combination) through increased thermogenesis and appetite suppression. Studies show users lose more fat and less lean mass vs controls. However, it is a natural compound (Ma Huang plant), banned in dietary supplements but OTC as bronchodilator, and banned by NCAA, MLB, NFL, PGA. Rated 5 as a powerful stimulant with documented side effects including cardiovascular events.

Overview

A sympathomimetic amine that works through both direct beta-receptor activation and indirect norepinephrine release to increase thermogenesis and metabolic rate. The classic fat burner, often stacked with caffeine and aspirin (ECA stack). The JAMA meta-analysis of ephedra/ephedrine trials shows ~0.9 kg/month weight loss above placebo. Carries significant cardiovascular risks.

Important Warnings

  • •Banned in dietary supplements in USA since 2004 - OTC only as bronchodilator
  • •Purchase limits: 3.6g/day, 9g/month, ID required (USA)
  • •Contraindicated with cardiovascular disease, hypertension, hyperthyroidism
  • •Do NOT combine with MAOIs - can cause hypertensive crisis
  • •47% of FDA adverse events involved cardiovascular system
  • •Serious adverse events include MI, stroke, and death
  • •Tolerance develops with prolonged use (cycle 4-6 weeks on, 2 weeks off)
  • •Banned by NCAA, MLB, NFL, PGA, and most sports organizations
  • •Crosses blood-brain barrier - CNS stimulant effects
  • •Less effective in patients on TCAs, reserpine, or with CHF

Purpose & Use Cases

Fat Loss/Thermogenesis

The JAMA meta-analysis (Shekelle et al. 2003) found ~0.9 kg/month weight loss above placebo (0.6-1.3 kg/month across combinations), alongside a 5-10% increase in energy expenditure. In the landmark 24-week Astrup et al. (1992) RCT, the ephedrine+caffeine group lost 16.6 kg vs 13.2 kg with placebo (3.4 kg more, p=0.0015).

Appetite Suppression

Approximately 75% of ECA stack's fat loss efficacy is attributed to decreased appetite. Only 25% from thermogenic effects.

Muscle Preservation During Cutting

Studies show ephedrine + caffeine users lose more fat mass and less lean body mass compared to controls during weight loss.

Energy/Stimulation

CNS stimulant effects provide energy and focus for training during caloric deficit.

Benefits

  • Meta-analysis (Shekelle et al. 2003, JAMA): ~0.9 kg/month weight loss above placebo (0.6-1.3 kg/month range)
  • Increases energy expenditure by 5-10%
  • 75% of effect from appetite suppression
  • Preserves lean mass during weight loss
  • Synergistic with caffeine (ECA stack)
  • 88% oral bioavailability
  • Extensive clinical trial data available
  • Relatively inexpensive

Good to Know

Most of the fat loss is appetite suppression, not "fat-burning"

It is easy to imagine ephedrine as a furnace, but roughly 75% of the ECA stack's effect comes from eating less and only ~25% from the thermogenic bump (a 5-10% rise in energy expenditure). If appetite is already well controlled, the added benefit is smaller than the hype suggests.

The "A" (aspirin) in ECA is largely optional and not risk-free

Aspirin was originally added on a prostaglandin-feedback theory to prolong thermogenesis, but the human evidence for it is weak and it adds GI/bleeding risk. Many now run just EC (ephedrine + caffeine). Honest take: the caffeine is the real synergist; the aspirin is close to legacy.

Tolerance builds by depleting norepinephrine. Cycle it, do not dose-escalate

Ephedrine works largely by releasing stored norepinephrine, so those stores deplete and the effect fades (tachyphylaxis). The correct response is cycling (e.g. a few weeks on, a break): not ramping the dose, which just raises cardiovascular and psychiatric risk without restoring the effect.

The cardiovascular ceiling is the whole story

Nearly half of FDA adverse-event reports for ephedra were cardiovascular, including MI and stroke. It is contraindicated with heart disease, hypertension and hyperthyroidism, must never be combined with MAOIs (hypertensive crisis), and should not be stacked with other stimulants like clenbuterol or yohimbine. Monitor BP and HR.

Legal and testing status is a minefield

Banned in US dietary supplements since 2004 (available only as an OTC bronchodilator with purchase limits and ID), prohibited in-competition by WADA above a 10 mcg/mL urine threshold, and banned by the NCAA and major pro leagues. "Natural plant extract" (Ma Huang) does not make it unregulated or test-safe.

Dosage Guidelines

Experience LevelDosage Range
Beginner20 – 40 mg/day
Intermediate50 – 75 mg/day
Advanced75 – 75 mg/day
Frequency
Split into 2-3 doses/day (commonly 20-25mg per dose); ranges above are total daily amounts. Avoid afternoon/evening dosing due to insomnia.
Typical Cycle Length
4 – 12 weeks
Notes

Standard ECA dose: 20-25mg ephedrine + 200mg caffeine + 81-325mg aspirin per dose, 2-3x daily (totaling ~50-75mg ephedrine/day). The landmark Astrup et al. (1992, Int J Obes) 24-week RCT used 20mg ephedrine + 200mg caffeine 3x daily (60mg/day total) and found it well tolerated, with side effects (tremor, insomnia, dizziness) reaching placebo levels by week 8. Community protocols commonly cite ~75-100mg/day as an upper ceiling beyond which cardiovascular/psychiatric risk rises with little added benefit (this ceiling is community-derived, not from a controlled trial). Start with a single dose to assess tolerance. Tachyphylaxis (tolerance) develops with prolonged use, many cycle short (e.g. 4-6 weeks on, 2 weeks off) even though the RCT above ran continuously for 24 weeks under supervision.

Half-Life

pH-dependent, with an average of ~6 hours.

Side Effects

Cardiovascular Effects

common
Severity
4/5

Tachycardia, hypertension, palpitations, arrhythmias. 47% of FDA adverse event reports involved cardiovascular system. Serious cases: MI, stroke.

Mitigation

Contraindicated with cardiovascular disease, hypertension. Monitor heart rate and BP. Avoid other stimulants.

CNS Stimulation

common
Severity
2.5/5

Restlessness, anxiety, insomnia, tremor, headache. 18% of FDA adverse events involved CNS.

Mitigation

Avoid dosing after early afternoon. Start with low dose. Reduce if anxiety is excessive.

Psychiatric Effects

rare
Severity
4/5

Paranoid psychoses, hallucinations, seizures reported with abuse or predisposition.

Mitigation

Do not exceed recommended doses. Avoid if history of psychiatric conditions.

Tachyphylaxis (Tolerance)

common
Severity
2/5

Effectiveness decreases with prolonged use as norepinephrine stores become depleted.

Mitigation

Cycle use (4-6 weeks on, 2 weeks off). Do not increase dose to overcome tolerance.

Gastrointestinal Effects

uncommon
Severity
1.5/5

Nausea, dry mouth, GI disturbances.

Mitigation

Take with food if needed.

General Mitigation Strategies

Start with single 20mg dose to assess tolerance. Never exceed 75mg/day. Avoid if you have cardiovascular disease, hypertension, anxiety disorders, or take MAOIs. Do not combine with other stimulants. Cycle use to prevent tolerance. Monitor heart rate and blood pressure. Meta-analysis showed 2.2-3.6 fold increase in psychiatric, autonomic, GI complaints, and palpitations vs placebo.

Support Supplements

Ancillary supplements commonly run alongside Ephedrine to manage side effects, support the target tissue, or fill nutrient demands it creates.

Blood pressure & heart rate monitoring

Key

Ephedrine reliably raises heart rate and blood pressure, and the serious adverse events (MI, stroke) are cardiovascular. A home BP cuff to track resting BP/HR is the single most useful safety habit, stop or reduce if readings climb.

Dose
Check resting BP/HR regularly, especially in the first weeks and after dose changes
Timing
Baseline before starting, then periodically

Potassium + magnesium (electrolytes)

Sympathomimetic/beta stimulation can shift electrolytes and contribute to palpitations and cramping, particularly when combined with caffeine and a caloric deficit.

Dose
Adequate dietary potassium; magnesium 300-400mg/day
Timing
Daily
When
Supportive; more relevant with higher doses or added stimulants.

Post Cycle Therapy (PCT)

✓PCT Not Required

Does not affect HPT axis. No PCT required.

How It Works

Ephedrine acts primarily through indirect mechanisms: inhibits norepinephrine reuptake and displaces norepinephrine from storage vesicles, increasing synaptic concentrations. Also directly activates alpha-1 (vasoconstriction), beta-1 (increased heart rate/contractility), and beta-2 (bronchodilation, vasodilation) adrenergic receptors. Crosses blood-brain barrier for CNS stimulant effects (releases norepinephrine and dopamine). Increases energy expenditure by 5-10%.

Fundamentals

Reference on the practices relevant to Ephedrine: how they are done and where they go wrong. Not a recommendation to use it.

Bloodwork: what to measure and when→

The markers that matter here

Warning signs & when to seek care→

When to stop and get help

Common Stacks

  • ECA Stack: Ephedrine 25mg + Caffeine 200mg + Aspirin 81mg (2-3x daily)
  • EC Stack: Ephedrine 25mg + Caffeine 200mg (aspirin benefit is debatable)
  • Ephedrine + T3 + Clenbuterol (advanced cutting stack, increased cardiovascular risk)
  • Do NOT combine with MAOIs, other stimulants, or in those with cardiovascular disease

WADA Status

⛔Prohibited by WADA
Category: S6. Stimulants
In-Competition: Prohibited

Ephedrine is prohibited in-competition only under S6 Stimulants. Threshold concentration of 10 mcg/mL in urine applies.

References

Last updated: July 18, 2026